Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.53 |
| ▸ | F10 | P00742 | 6/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.49 |
| ▸ | PRKX | P51817 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1804308 | 0.90 | F10 (0.53) | F10PRSS1FAAH | |
| SCHEMBL2598185 | 0.90 | F10 (0.53) | F10PRSS1FAAH | |
| SCHEMBL1804309 | 0.90 | F10 (0.53) | F10PRSS1FAAH | |
| SCHEMBL14351264 | 0.90 | F10 (0.49) | S1PR5F10PRSS1S1PR1FAAH | |
| SCHEMBL4661703 | 0.85 | RORC (0.57) | F10PRSS1 | |
| SCHEMBL5110560 | 0.85 | RORC (0.57) | F10PRSS1 | |
| SCHEMBL7888069 | 0.85 | RORC (0.57) | F10PRSS1 | |
| SCHEMBL14498495 | 0.85 | RORC (0.57) | F10PRSS1 | |
| SCHEMBL4661705 | 0.85 | RORC (0.57) | F10PRSS1 | |
| SCHEMBL23417389 | 0.85 | F10 (0.54) | F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | PYM1, GPR119, GLP1R | S1PR5 2008/4885F10 728/4885PRSS1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.